Shaleem Jacob

Co-Founder & CSO | Ph.D. Biotechnology | University of Cambridge

London, England, United Kingdom

About

With over a decade of experience in chemical and biochemical engineering, I co-founded VectorisBio to spearhead advancements in viral vector purification. At VectorisBio, I focus on developing scalable, affinity-based processes that align with our mission to innovate solutions for the biopharmaceutical industry. My work is driven by a commitment to leveraging diverse collaboration and expertise to tackle industry challenges and promote impactful health solutions globally. At VectorisBio, I lead R&D efforts with a strong foundation in biotechnology, protein purification, and chromatography. My experience spans partnerships with leading institutions such as the Gates Foundation and regulatory bodies like the MHRA, ensuring our team creates cutting-edge purification processes to meet industry needs.

Experience

  • Co-Founder and Chief Scientific Officer at VectorisBio
    May 2025 - Present · 1 yr 3 mos

    Driving innovation in viral vector purification by leading R&D and developing scalable affinity-based processes, leveraging 10+ years’ experience

  • Advisor at ReceiptNet
    Oct 2024 - Sep 2025 · 1 yr

    Advisory to the Founding team. Supported by Innovate UK

  • Research Fellow in Novel Vaccine Manufacturing Characterisation at UCL
    Mar 2021 - Oct 2024 · 3 yrs 8 mos

    Bill and Melinda Gates Foundation (BMGF) funded collaboration - UCL Vax-Hub Initiative. Collaborative project with the Jenner Institute, University of Oxford, Vaccine Analytics and Formulation Center (VAFC), The University of Kansas and London School of Hygiene and Tropical Medicine

  • Process Development Scientist at Oxford Biomedica
    Feb 2019 - Mar 2021 · 2 yrs 2 mos

  • PDRA (Vaccine Development Group, funded by the Bill and Melinda Gates foundation) at UCL
    Jan 2017 - Feb 2019 · 2 yrs 2 mos

    My research focuses on the process development and downstream processing of rotavirus vaccines. The project is in collaboration with MIT, Kansas University, PATH and the Gates Foundation.